by Madaline Spencer | Jul 3, 2025
The U.S. Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still’s disease. Still’s disease is a rare systemic inflammatory...
by Madaline Spencer | Jul 3, 2025
Krish Patel, MD, Medical Oncologist at Sarah Cannon Research Institute, discusses first results from a study evaluating CAR-T cell therapy for large B cell lymphoma (LBCL). LBCL is a form of non-Hodgkin lymphoma. Lymphomas occur when cells of the immune...
by Madaline Spencer | Jul 2, 2025
Andrew T. Kuykendall, MD, Associate Member in the Department of Hematology at Moffitt Cancer Center, discusses results from the VERIFY clinical trial in polycythemia vera (PV). PV is a rare condition characterized by an increased number of red blood...
by Madaline Spencer | Jul 1, 2025
Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses results from the CEPHEUS clinical trial in multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by a serum...
by Madaline Spencer | Jun 30, 2025
Dirk Arnold, MD, PhD, Director of the Asklepios Tumorzentrum Hamburg, discusses the OrigAMI-2 clinical trial in left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Approximately 50% of patients diagnosed with colorectal cancer have...
